Press Room

INTERPHEX Week Tokyo 2025

Start
Wednesday, July 09, 2025
End
Friday, July 11, 2025
Location: Tokyo, Japan
Booth Number: W1-29

Hovione is exhibiting at INTERPHEX Week Tokyo, a renowned meeting place for the pharmaceutical industry, bringing together worldwide professionals and leading companies for networking and business opportunities. 

Meet the Hovione team at booth # W1-29

  • Gain insights on how Hovione is addressing solubility and bioavailability challenges and how, with our unrivalled expertise in formulation development, scale-up and GMP manufacturing, we can support you in developing novel drugs that make a difference for patients.
  • Understand how we ensure your inhalation and nasal therapies are engineered for success, from start to finish. With active business in Japan since the 1960s, Hovione is the right partner when looking for a one-site solution that includes a full range of innovative devices.
  • Learn how our latest technologies and innovations in drug product development can support your projects providing optimal solutions with the right scale and flexibility. 

Yuken Kyoyama and Yasushi Usuda are looking forward to meeting you.

 

Schedule a meeting today.

schedule a meeting

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025